F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comAarti Drugs Limited is a leading pharmaceutical company in India, engaged in the production of Active Pharmaceutical Ingredients (APIs), pharmaceuticals, and specialty chemicals. With a consistent presence in both domestic and international markets, Aarti Drugs has built a reputation for quality, innovation, and export strength.
In this article, we’ll explore Aarti Drugs share price targets from 2025 to 2030, along with its business overview, financial position, and shareholding pattern to help investors make informed decisions.
| Detail | Value |
|---|---|
| Open | ₹474.80 |
| Previous Close | ₹471.00 |
| Day’s High | ₹481.30 |
| Day’s Low | ₹466.25 |
| VWAP | ₹473.79 |
| 52-Week High | ₹635.00 |
| 52-Week Low | ₹312.00 |
| All-Time High | ₹1,026.95 |
| All-Time Low | ₹1.64 |
| Market Capitalization | ₹4,352 Cr |
| Face Value | ₹10 |
| Book Value per Share | ₹139.96 |
| Dividend Yield | 0.21% |
| 20D Avg Volume | 2,13,025 |
| 20D Avg Delivery (%) | 39.98 |
Established in 1984, Aarti Drugs is part of the Aarti Group of Industries, a diversified business house with strong expertise in chemicals and pharmaceuticals. The company is one of the largest API producers in India, catering to therapeutic segments such as anti-inflammatory, anti-diabetic, anti-fungal, and cardiovascular drugs.
Aarti Drugs has a strong export presence across more than 100 countries, contributing significantly to its revenues. Its robust R&D capabilities and manufacturing efficiency make it a preferred partner for global pharmaceutical companies.
One of India’s top API manufacturers.
Exports to over 100 countries worldwide.
Consistent focus on R&D and product innovation.
Diversified therapeutic segments ensuring stable revenue streams.
Commitment towards sustainability and cost-efficient production.
| Investor Type | Holding (%) |
|---|---|
| Promoters | 55.22% |
| Retail & Others | 32.58% |
| Mutual Funds | 9.85% |
| Foreign Institutions | 2.26% |
| Other Domestic Institutions | 0.09% |
This pattern highlights strong promoter confidence and steady institutional participation, while retail investors also form a significant base.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 500 | 550 |
| 2026 | 570 | 620 |
| 2027 | 640 | 700 |
| 2028 | 720 | 800 |
| 2029 | 820 | 900 |
| 2030 | 920 | 1,000 |
These targets are based on Aarti Drugs’ market position, earnings growth, expanding export potential, and industry trends in the pharmaceutical sector.
Aarti Drugs is expected to show gradual price appreciation by 2025 due to stable API demand and strong exports.
Why?
Stable API demand across therapeutic segments.
Rising exports in the regulated markets.
Controlled input costs due to efficient sourcing.
Investment Advice: Good for staggered investments; watch Q3 and Q4 earnings for growth visibility.
In 2026, revenue growth and export expansion could push valuations higher.
Why?
Expanding partnerships with global pharma companies.
R&D-driven new product launches.
Strong promoter holding ensures stability.
Investment Advice: Suitable for long-term investors focusing on pharma growth.
By 2027, the company may strengthen its export dominance and benefit from higher API demand.
Why?
Increasing penetration in emerging markets.
Diversification in specialty chemicals.
Cost efficiency and strong margins.
Investment Advice: Hold positions; potential for long-term CAGR growth.
Aarti Drugs could cross ₹750 comfortably with continued expansion in APIs and formulation business.
Why?
Strong balance sheet with low debt.
Government support for domestic API manufacturing.
Rising healthcare demand globally.
Investment Advice: Good time to accumulate for portfolio diversification.
The pharma sector’s global boom could place Aarti Drugs in a favorable growth cycle.
Why?
Higher exports to the US and Europe.
Improving EPS with better margins.
Growing presence in anti-diabetic and cardiovascular segments.
Investment Advice: Recommended for medium to long-term investors.
By 2030, Aarti Drugs could touch the four-digit mark with strong fundamentals and global recognition.
Why?
Consistent export-led growth.
Strong leadership and management.
Diversified product pipeline and sustainable practices.
Investment Advice: Excellent choice for long-term wealth creation.
Yes, Aarti Drugs is a fundamentally strong company with a proven track record in the pharma sector. Its global reach, diversified product base, and R&D-driven strategy make it a potential multibagger for long-term investors.
Strong promoter holding (55.22%).
Increasing export potential.
Healthy book value and consistent earnings.
Diversified therapeutic portfolio.
Fluctuations in raw material prices.
Global regulatory challenges.
Pharma sector dependency on approvals and compliance.
Always consult a certified financial advisor before investing.
Aarti Drugs is one of India’s most promising pharma companies listed on NSE and BSE. With its robust manufacturing base, export strength, and diversified therapeutic offerings, it stands as a reliable option for investors.
Currently, the share trades around ₹474.80, and analysts believe it could potentially reach ₹1,000 by 2030, making it a good pick for long-term portfolios.
Investors should monitor quarterly earnings (especially Q2 and Q4) and global pharma trends to make the most of this stock.
1. What is the current Aarti Drugs share price?
As of August 2025, the price is around ₹474.80.
2. What is the Aarti Drugs share price target for 2025?
The share price target for 2025 is ₹500 – ₹550.
3. Will Aarti Drugs reach ₹1,000 by 2030?
Yes, based on growth trends and fundamentals, it is projected to reach ₹920 – ₹1,000 by 2030.
4. Is Aarti Drugs a good stock to buy?
Yes, for long-term investors, Aarti Drugs offers growth opportunities in the pharma space.
5. What is the promoter holding in Aarti Drugs?
Promoters hold about 55.22% of the company.
6. What is the 52-week high and low of Aarti Drugs?
52-week high is ₹635.00 and 52-week low is ₹312.00.
7. Does Aarti Drugs pay dividends?
Yes, though the dividend yield is relatively low at 0.21%.
8. What is the market capitalization of Aarti Drugs?
It stands at around ₹4,352 Crores.
9. How does Aarti Drugs generate revenue?
Primarily through APIs, formulations, and exports.
10. Is Aarti Drugs suitable for SIP investments?
Yes, investors can consider staggered SIP-based investments for long-term wealth creation.
???? Disclaimer: This article is for educational purposes only. Please seek expert financial advice before making any investment decisions.
Register & Login